ArticleNeurology2025
Randomized Phase 2 Study of FcRn Antagonist Efgartigimod in Generalized Myasthenia Gravis.
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it
ArticleNeurology2025
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.